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Abstract
Background: Regulators of G protein signaling (RGSs) accelerate GTP hydrolysis by Gα subunits
and profoundly inhibit signaling by G protein-coupled receptors (GPCRs). The distinct expression
patterns and pathophysiologic regulation of RGS proteins suggest that inhibitors may have
therapeutic potential. We recently described a focused one-bead, one-compound (OBOC) library
screen to identify peptide inhibitors of RGS4. Here we extend our observations to include another
peptide with a different mechanism of action.
Results:  Peptide 5nd  (Tyr-Trp-c [Cys-Lys-Gly-Leu-Cys]-Lys-NH2, S-S) blocks the RGS4-Gαo
interaction with an IC50 of 28 μM. It forms a covalent, dithiothreitol (DTT) sensitive adduct with a
mass consistent with the incorporation of one peptide per RGS. Peptide 5nd activity is abolished
by either changing its disulfide bridge to a methylene dithioether bridge, which cannot form
disulfide bridges to the RGS, or by removing all cysteines from the RGS protein. However, no single
cysteine in RGS4 is completely necessary or sufficient for 5nd activity.
Conclusion: Though it has some RGS selectivity, 5nd appears to be a partially random cysteine
modifier. These data suggest that it inhibits RGS4 by forming disulfide bridges with the protein.
Background
G Protein-Coupled Receptors (GPCRs) are a family of
over 800 proteins that contain seven transmembrane
regions [1]. When activated by agonists, such as hor-
mones, neurotransmitters, drugs, or photons of light,
GPCRs stimulate exchange of GTP for GDP on the Gα
subunit of the heterotrimeric G protein, which then
undergoes an activating conformational change that
allows it and its associated βγ subunit to interact with
effector proteins [2]. This can result in a number of down-
stream signaling events including changes in membrane
potential, neurotransmitter or hormone release, gene
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transcription or other cellular events [1]. The Gα subunit
inactivates itself by hydrolyzing GTP to GDP allowing
reassociation with Gβγ and the receptor. Unlike GTPase
accelerating proteins (GAPs) for small G-Proteins, regula-
tors of G protein signaling (RGS) proteins bind to the acti-
vated Gα protein and stabilize the transition state for GTP
hydrolysis without directly interacting with the nucleotide
[3,4]. This accelerates GTP hydrolysis and inactivation of
the G-protein, and inhibits cell responses to GPCR signal-
ing.
We recently reported the screening of a focused, one-bead,
one-compound (OBOC) peptide library for inhibitors of
RGS4 [5]. This library was focused to include features
known to be necessary for the activity of a lead peptide,
YJ34  (Ac-Val-Lys-c [Cys-Thr-Gly-Ile-Cys]-Glu-NH2, S-S)
which mimics the switch 1 region of Gα to bind to RGS4
and prevent its GAP activity [6]. This screen yielded two
peptides, which have YJ34-like activities and, based on
our models, bind the predicted YJ34 site on RGS4. Here
we describe a third peptide from the library screen that has
a different mechanism of action. The data presented here
suggest that peptide 5nd  (Tyr-Trp-c [Cys-Lys-Gly-Leu-
Cys]-Lys-NH2, S-S, peptide 7nd in Roof et al, 2008), is a
partially random cysteine modifier that inhibits RGS4
through disulfide bond formation between the peptide
and the RGS.
Results and discussion
We recently described a bead-based screen in which 2.5 ×
106 different peptide sequences were prepared as a OBOC
library [5]. Fluorescently labeled RGS4 was used to probe
the library for peptides that bind RGS4 [5]. A total of 14
peptide sequences were obtained and, in our first report,
one peptide sequence (in two chemical forms) was found
to inhibit RGS4-stimulated GTPase activity. Since the
majority of those hit peptides could bind tightly to the
RGS without disrupting GAP activity, they were also tested
in the flow cytometry protein interaction assay (FCPIA)
(Figure 1), which measures the interaction between RGS4
and Gαo. In this method we used a Luminex flow cytom-
eter to detect the binding of Alexa Fluor 532-labeled Gαo
to biotinylated RGS4 on avidin beads in the presence of
AMF (AlCl3, MgCl2, NaF and GDP) to put the Gα subunit
into a transition state-like conformation [7]. Peptides
were tested at 50 μM except where limited by solubility
(Table 1). Fourteen peptide sequences obtained from the
OBOC screen, in both acetylated, disulfide bridged (ad)
or free N-terminal disulfide bridged (nd) versions (or 28
peptides total), were tested and 5 showed statistically sig-
nificant inhibition of the RGS4-Gαo interaction in the
FCPIA assay (2nd, 5nd, 5ad, 6nd and 6ad, Figure 1, Table
1). Peptide 5 was the most active (80 ± 5 and 37 ± 3 per-
cent inhibition for 5nd and 5ad, respectively) (Figure 1).
5nd inhibited Gαo binding to a number of different RGS
proteins (Figure 2). The IC50 values are 28 μM, 43 μM, 66
μM, ~145 μM and ~175 μM for RGS4, RGS8, RGS16,
RGS19 and RGS7, respectively (logIC50 of -4.56 ± 0.02, -
4.36 ± 0.02, -4.18 ± 0.03, ~-3.84 ± 0.05 and ~-3.76 ±
0.08). The most potent effects were on RGS4, RGS8 and
RGS16, which all belong to the same RGS family (R4) and
share the greatest sequence homology. RGS19 and RGS7
are in the RZ and R7 families, respectively and show less
inhibition by 5nd. Linear as well as bridged versions of
peptide 5 were tested in the FCPIA since cyclization yields
would most likely have been less then 100% in the syn-
thesis of the library leaving some linear peptides present
on each bead. The free N-terminal linear (nl) and
acetylated linear (al) peptides were found to be inactive (-
1 ± 10 and -2 ± 4 percent inhibition for 5nl and 5al,
respectively) (Figure 2C). This may be due to lack of struc-
tural rigidity necessary for the correct interaction of the
peptide with the RGS protein or a role for chemical reac-
tivity of the disulfide.
We next wanted to determine the mechanism of action of
peptide 5. A small molecule inhibitor of RGS4, methyl N-
[(4-chlorophenyl)sulfonyl]-4-nitrobenzenesulfinimi-
doate (CCG-4986) was identified in a FCPIA screen and
found to interact with RGS4 through cysteine modifica-
tion ([7,8], David Roman, in preparation). We wanted to
determine if peptide 5nd acts in a similar manner. When
biotin-RGS4 on avidin beads was treated with 5nd, fol-
lowed by washing of the beads, the inhibition of RGS4-
Gαo interactions was not reversed (75 ± 11 percent inhibi-
tion remained). Inclusion of dithiothreitol (DTT) in the
wash buffer significantly decreased 5nd activity (15 ± 4
percent inhibition) (Figure 3A). These data suggest that
the peptide may bind irreversibly through a disulfide
bridge. To further investigate this possibility, a free N-ter-
minal, methylene dithioether bridged peptide, 5nm
(Table 1), was synthesized and found to be inactive (3 ±
0.1 percent inhibition) (Figure 3A). Since the methylene
dithioether bridged peptide would be incapable of form-
ing a disulfide bond with RGS4, this result supports the
hypothesis that 5nd forms a functionally critical disulfide
bridge with RGS4. Although, it is also possible that the
structural change from the increased bridge length is
responsible for the loss of activity of 5nm compared to
5nd. A similar pattern was seen with RGS8; the loss of
activity of 5nd on RGS8 was much greater with washing if
DTT was included in the buffer and 5nm had only a small
effect on RGS8 activity (64 ± 2, 50 ± 3, 10 ± 3, and 18 ± 1
percent inhibition for 5nd no wash, 5nd wash, 5nd DTT
wash and 5nm respectively) (Figure 3B).
To directly test for the formation of a covalent adduct
between 5nd and RGS4, we performed mass spectrometry
(MS) analysis. The RGS4Δ51N protein, following TEV-BMC Pharmacology 2009, 9:9 http://www.biomedcentral.com/1471-2210/9/9
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protease cleavage from the MBP-His6  construct, was
treated with 5nd at a 50:1 molar ratio. An adduct to the
protein that is consistent with the mass of 5nd binding
through a disulfide bridge was observed by MS (Figure 4,
mass shift observed: Δ999.2 ± 1; expected: Δ998.5). No
such shift was observed with DMSO-treated RGS4Δ51N.
There is also a small peak that may represent two peptides
per RGS (observed: Δ1999.1 ± 2; expected: Δ1997.0).
Since 5nd forms an irreversible, DTT-sensitive bond with
RGS, it was suspected that it binds covalently to a cysteine
in the protein through a disulfide bridge. Indeed, removal
of all 7 cysteines (termed the -7C mutant) from RGS4
greatly diminished 5nd activity (logIC50 of -3.24 ± 0.14
for -7C vs. -4.36 ± 0.02 for wild type) (Figure 5, Table 2).
Removal of cysteines from the C-terminus of RGS4 had no
effect on the potency of 5nd (logIC50 -4.5 ± 0.2) while
removal of all 4 cysteines from the RGS domain did
reduce the potency of compound by 3.6-fold (logIC50 -3.8
± 0.2) (Figure 5E, Table 2). These results suggest a com-
plex mechanism involving cysteines in both the C-termi-
nus and RGS domain based on the discrepancy in 5nd
potency on the -7C mutant and the protein with no cys in
the RGS domain.
To further explore the role of cysteine residues, the RGS
proteins tested in Figure 2 were aligned with RGS4 (Figure
6) to identify shared cysteines. Based on the conservation
Hit peptides in the FCPIA Figure 1
Hit peptides in the FCPIA. Hit peptides from Roof, et al. 2008 were tested at 50 μM unless otherwise indicated for ability 
to disrupt the RGS4-Gαo interaction as described using 25 nM Gα o-Alexa Fluor-532 and 5 nM wild type RGS4-biotin (mean ± 
S.E.M., n ≥ 3) *p < 0.05, **p < 0.01, ***p < 0.001 compared to no peptide.
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of Cys95 and Cys148 in RGS4 RGS8 and RGS16, which
are all inhibited by 5nd, it was hypothesized that those
cysteines may be involved in the peptide's activity. How-
ever, removing those cysteines individually (i.e. in the
C95A and C148A mutant RGS4) did not diminish 5nd
activity (logIC50 -4.71 ± 0.0.5 and -4.27 ± 0.05 for C95A
and C148A, respectively) (Figure 5A, Table 2). Because all
the mutants used in this manuscript bound Gαo in an
AMF-dependent manner with reasonable affinities com-
pared to wild type (Table 2), it is reasonable to assume
they are folded properly. With the assumption that 5nd
would have to bind within the RGS domain to inhibit Gαo
binding, C71A and C132A mutations were also tested.
The C71A mutation did not affect 5nd activity (logIC50 -
4.34 ± 0.06). The C132A mutation did decrease 5nd
potency, but only partially (logIC50 -3.86 ± 0.07) (Figure
5B, Table 2). Interestingly, C132 is near the Gα binding
site, which is also the suggested YJ34 binding site. It is
tempting to speculate that one of the multiple sites of
action of 5nd is adjacent to the Gα binding site (similar to
that of YJ34), however, the A132C "add back" mutant dis-
cussed below again suggests a complex scenario.
The previous experiments tested which cysteines are nec-
essary for inhibition by 5nd. In an alternative approach,
we added cysteines back to the -7C mutant to determine
which might be sufficient for 5nd activity. Surprisingly,
no single A to C mutation within the RGS domain of the
-7C mutant even partially restored 5nd activity; not even
the A132C mutant (Figure 5C, Figure 5D, Table 2). This
suggests that 5nd inhibits RGS4/Gαo interactions by bind-
ing to multiple cysteines – probably in both the RGS
domain and the C-terminus. Furthermore, Cys132 is
involved in the actions but this is clearly not sufficient to
Table 1: Hit peptide names, sequences and physical properties
Name Sequence cyclization Buffer Solubility (μM) ALogP % Inhibition of RGS4-Gαo
YJ34 Ac-VKCTGICE-NH2 S-S 80 -2.58 -17 ± 4 (40 μM)
1nd YNCQGECK-NH2 S-S ≥ 420 -2.8 2 ± 4
1ad Ac-YNCQGECK-NH2 S-S 123 -2.37 14 ± 6
2nd GTCFGTCW-NH2 S-S 464 -0.37 19 ± 3**
2ad Ac-GTCFGTCW-NH2 S-S 30 0.08 10 ± 4 (10 μM)
3nd LVCKGYCQ-NH2 S-S ≥ 470 -0.37 12 ± 2
3ad Ac-LVCKGYCQ-NH2 S-S 427 0.17 10 ± 3
4nd KVCMGGCT-NH2 S-S ≥ 470 -2.02 4 ± 3
4ad Ac-KVCMGGCT-NH2 S-S 459 -2.09 9 ± 6
5nl YWCKGLCK-NH2 Linear 465 1.46 -1 ± 10
5al Ac-YWCKGLCK-NH2 Linear 460 1.66 -2 ± 4
5nd* YWCKGLCK-NH2 S-S 463 0.48 80 ± 5***
5ad* Ac-YWCKGLCK-NH2 S-S 464 1.04 37 ± 3***
5nm YWCKGLCK-NH2 S-me-S ≥ 470 0.53 3 ± 0.1 (100 μM)
6nd* KHCYGFCY-NH2 S-S Low 0.94 23 ± 15 (25 μM) *
6ad* Ac-KHCYGFCY-NH2 S-S 421 1.24 27 ± 4***
Solubility in buffer was determined experimentally by HPLC. ALogP calculations are from http://www.vcclab.org, [9]. Percent inhibition values (50 
μM unless otherwise stated) are from Figure 1, 2C, or 3A (mean ± S.E.M., n ≥ 3) *p < 0.05, **p < 0.01, ***p < 0.001 compared to no peptide. 
Peptides with significant inhibition in the FCPIA are in bold. *Peptides 5 and 6 were previously reported as peptides 7 and 14, respectively in Roof 
et al 2008.BMC Pharmacology 2009, 9:9 http://www.biomedcentral.com/1471-2210/9/9
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explain them. Thus it is concluded that 5nd is at least par-
tially non-selective in its cysteine modification. These data
also suggest RGS4 is more sensitive to covalent redox
manipulations than are the other RGS proteins tested.
In summary, peptide 5nd  binds covalently through
disulfide bridges with cysteines in the protein and it raises
some interesting points regarding the previously reported
focused OBOC screen [5]. First, it is interesting that
although the library was focused to include features nec-
essary for YJ34  activity, peptide 5nd  was isolated that
clearly works through a different mechanism. This was
unexpected since the library was biased towards peptides
that would have the same mechanism as the lead com-
pound. However, this bias is by no means a guarantee.
Indeed, there is no way to know whether a peptide like hit
2, (which has YJ34-like activities and is modeled to bind
the putative YJ34 site on RGS4, [5]) would have been
found from a completely random library.
Another interesting observation is that RGS4 is preferen-
tially inhibited by the cysteine modifier peptide over
other RGS proteins. This could be because the peptide
binds selectively to a pocket on RGS4, or because RGS4 is
Characterization of hit 5 Figure 2
Characterization of hit 5. A) and B) Dose response curves for 5nd in the FCPIA with different RGS proteins (RGS Family), 
(mean ± S.E.M., n = 3) *p < 0.05, **p < 0.01, ***p < 0.001 compared to RGS4 at the same 5nd concentration. C) Peptides were 
tested at 50 μM as in Figure 1, (mean ± S.E.M., n ≥ 3) *p < 0.05, **p < 0.01, ***p < 0.001 compared to no peptide.
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particularly susceptible to cysteine modification. This lat-
ter possibility is supported by the observation that a small
molecule inhibitor of RGS4, CCG-4986, that was identi-
fied in an FCPIA screen appears to inhibit RGS4 through
covalent modification of cysteines while having no activ-
ity against RGS8 ([7,8], David Roman, in preparation).
Also, RGS4 is more sensitive to inhibition with N-ethyl-
maleimide, (a cysteine modifier) than RGS8 (David
Roman, personal communication). Unlike 5nd, CCG-
4986 appears to selectively modify 1 or 2 cysteines in the
RGS4 ([7,8], David Roman, in preparation). This
increased cysteine selectivity may be why CCG-4986 has
more RGS selectivity than 5nd. However, since all pep-
tides in our library have a disulfide bond, it is not clear
why 5nd (and 5ad) would be so much more potent at
covalently modifying RGS4. Perhaps the cysteine reactive
peptide also has some affinity for a specific pocket on the
RGS.
A third observation is that there may be a correlation
between peptide logP and activity in the FCPIA (Table 1).
The order of activity in the FCPIA is hit 5>hit 6>hit 2> oth-
ers [9], while the order of hydrophobicity is hit 6>hit
5>hit  3>hit 2> others. Given the considerable error in
computational logP calculations [10], it is reasonable to
suggest at least qualitatively that the most hydrophobic
peptides have the greatest activity. This also tells us some-
thing about RGS4. These data suggest that RGS4 binding
sites, including unidentified binding sites, have hydro-
phobic surfaces and investigators should be mindful of
this when choosing libraries for future screens.
Conclusion
We report the identification and characterization of a pep-
tide RGS4 inhibitor with a novel mechanism involving
cysteine-modification. Although our focused OBOC
screen did not improve on the potency of existing RGS4
inhibitors with, these data illustrate points that should
result in improved screens in the future.
Methods
Materials
Fmoc-protected amino acids and Rink amide resin were
purchased from Advanced ChemTech. Peptide synthesis
grade chemicals were purchased from Applied Biosys-
tems. Avidin coated microspheres were purchased from
Luminex.
Irreversibility experiments Figure 3
Irreversibility experiments. RGS-biotin on avidin beads was treated with 5nd (100 μM) or 5nm (100 μM) and then 
washed in buffer (with or without 1 mM DTT) or not washed and put in the FCPIA using RGS4 (A) or RGS8 (B) (mean ± 
S.E.M., n ≥ 2) *p < 0.05, **p < 0.01, ***p < 0.001 compared to no peptide (100%); #p < 0.05, ##p < 0.01, ###p < 0.001 com-
pared to 5nd no wash.BMC Pharmacology 2009, 9:9 http://www.biomedcentral.com/1471-2210/9/9
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MS analysis of RGS4 with and without 5nd pretreatment Figure 4
MS analysis of RGS4 with and without 5nd pretreatment. RGS4Δ51N was cleaved from the MBP-His6 construct and 
subject to MALDI MS after pretreatment with DMSO (A) or 5nd (250 μM) (B). Both spectra show the region between 4,000 
and 30,000 m/z and have the peak at 18158.8 or 18158.2 m/z for A and B, respectively, which corresponds to the cleaved 
RGS4Δ51N protein (black arrows). The spectrum in B also has a peak at 19158 m/z that corresponds to a peptide adduct (grey 
arrows). There is a very small peak at 20157.9 that may correspond to 2 peptides per RGS (grey arrows). The inset is a blow-
up of the region between 17500 and 20500 m/z.BMC Pharmacology 2009, 9:9 http://www.biomedcentral.com/1471-2210/9/9
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Protein Expression, Purification and Labeling
Proteins were expressed, purified and labeled as described
previously [5]. The mutagenesis was done using the
"QuickChange Multi Site-Directed Mutagenesis Kit" from
Stratagene according to the manufacturer's protocol. The
construct of RGS4 used in these studies is a maltose bind-
ing protein (MBP-) fusion protein of the RGS4 sequence
from which the amphipathic N-terminal helix has been
removed (i.e. MBP-RGS4Δ51N). For simplicity in the text,
this will be referred to as RGS4. All other RGS proteins
were human sequences and were used as Mpb fusions:
RGS7 RGS domain (aa: 305–453), RGS8 full length,
RGS16 full length, and RGS19ΔC11 (amino acids 1–209).
To cleave RGS4Δ51N from the MBP-His6 construct for MS
analysis, MBP-His6-RGS4Δ51N was treated with 15%
MBP-His6-TEV protease S219V [11] for 22 hours at 4°C
and purified over a Ni-NTA column.
Peptide Synthesis
Soluble peptides were synthesized on Rink resin, cleaved
and cyclized as described previously [6]. Peptide purity (at
least 95%) and solubility were verified by high-perform-
ance liquid chromatography and correct mass was verified
by MS analysis [6]. ALogP calculations are from http://
www.vcclab.org[9]. Peptides were prepared as 5 mM
stocks in DMSO.
Dose curves of 5nd on various RGS4 cysteine mutants Figure 5
Dose curves of 5nd on various RGS4 cysteine mutants. Various concentrations of 5nd were tested for disruption of 
the RGS4-Gαo interaction for C95A (5 nM), or C148A (5nM) (A), C71A (5nM) or C148A (5nM) (B), A95C in the -7C (5nM), 
or A132C in the -7C (5nM) (C), A71C in the -7C (5nM), or A148C in the -7C (5nM) (D) or the mutant with no cysteines in 
the domain (20 nM) or the C-terminus (20 nM) (E) in the FCPIA (mean ± S.E.M., n ≥ 3). See Table 2 for statistics.
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FCPIA (Flow Cytometry Protein Interaction Assay)
FCPIA was performed as previously published [7].
Mass Spectrometry
Total mass MS of 5 μM RGS4Δ51N was analyzed on a
MicroMX MALDI MS instrument in positive ion mode
with an accuracy of ± 0.1% after pretreatment with DMSO
or 250 μM 5nd. The sample was run over a desalting col-
umn prior to MS analysis. MS analysis was performed at
the Protein Structure Facility at the University of Michi-
gan.
Statistical Analysis
Data are expressed as mean ± S.E.M (or ± S.D for n = 2)
and analyzed by one-way ANOVA. Dose curves were con-
strained with maximum and minimum at 100% and 0%,
respectively. Statistics for Figure 5 are included in Table 2
instead of on the graph for simplicity. Significance is indi-
cated as follows: *p < 0.05, **p < 0.01, ***p < 0.001.
Analysis was performed using Graphpad Prism.
Abbreviations
AMF: AlCl3, MgCl2, NaF and GDP; ANOVA: analysis of
variance; DMSO: dimethylsulfoxide; DTT: dithiothreitol;
GAP: GTPase accelerating protein; GPCR: G protein-cou-
pled receptor; GTP: guanosine triphosphate; FCPIA: flow
cytometry protein interaction assay; OBOC: one-bead,
one-compound; RGS: regulator of G protein signaling;
SAR: structure activity relationship.
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